

Dr. Reddy's, Hetero sign voluntary licensing agreement with Gilead Sciences to transform global HIV response

03 October 2024 | News

Expanding access to groundbreaking Lenacapavir to 120 high-incidence countries



Hyderabad-based Hetero and Dr. Reddy's have inked new partnership with Gilead Sciences Ireland UC, a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs).

This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis (PrEP).

This collaboration marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions. Lenacapavir is a breakthrough HIV-1 capsid inhibitor that works with other antiretroviral drugs to treat multi-drug-resistant HIV-1 infections. It has a unique ability to target multiple stages of the HIV lifecycle, making it highly effective for patients with limited treatment options.

Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022. It is a first-in-class HIV-1 capsid inhibitor.